Heart Failure Clinical Trial
Official title:
Isolated Resistance Training Program Versus Combined With Neuromuscular Electrical Stimulation for Femoral Quadriceps in Patients With Femoral Intra Aortic Balloon Pump: a Randomized Controlled Trial
The objective of this randomized clinical trial is to compare the effects of a standardized exercise program alone versus the same program combined with neuromuscular electrical stimulation in patients undergoing heart failure . The main questions it aims to answer are: - Assessing the ultrasonographic parameters: echo intensity (echogenicity), cross-sectional area, thickness, and pennation angle of the rectus femoris muscle in both lower limbs. - Evaluating the strength of the femoral quadriceps muscle - Evaluating the changes in the chronaxie of the rectus femoris muscle in both lower limbs. The protocol will have a total duration of 35 days, with an initial intervention period of 21 days (5 days per week), followed by a 14-day follow-up period.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 18, 2026 |
Est. primary completion date | March 18, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Intra-aortic balloon pump (IABP) for more than 48 hours - Dobutamine = 20 mcg/kg/min - Norepinephrine = 0.2 mcg/kg/min (35) - Absence of device failures or bleeding in the last 24 hours - Mean arterial pressure (MAP) = 60 mmHg and = 120 mmHg - Heart rate (HR) = 60 bpm and = 120 bpm - Absence of neurological event with previous cognitive or motor deficit - Presence of untreated deep venous thrombosis - Absence of previous autoimmune diseases - Absence of previous rheumatic diseases Protocol Discontinuation Criteria: - Need for norepinephrine > 0.2 mcg/kg/min - Acute arrhythmia of any etiology with hemodynamic instability - Hemodynamic instability: MAP < 60 mmHg or >120 mmHg or HR < 60 bpm or > 120 bpm - Occurrence of neurological event with cognitive or motor deficit Exclusion Criteria: - Need for invasive mechanical ventilatory support - If the patient or responsible family member fails to sign or withdraws the informed consent |
Country | Name | City | State |
---|---|---|---|
Brazil | Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To investigate echo intensity of the rectus femoris muscle. | The ultrasonographic images will be obtained by a portable device in B-mode, using a 6 cm linear array transducer with a frequency range of 6-13MHz. The echointensity value will be acquired through quantitative analysis using the square method, in grayscale, where the average value will be calculated using the histogram function of the dedicated software, in arbitrary units (AU). | The data will be collected on the day of protocol initiation (Day 0), after 14 days (Day 14), 21 days (Day 21), and 35 days (Day 35). | |
Secondary | To investigate cross-sectional area of the rectus femoris muscle. | The cross-sectional area will be determined by the number and size of individual fibers within the rectus femoris muscle, using the measurement of the anatomical area (cross section of a muscle perpendicular to its longitudinal axis) in centimeters square. | The data will be collected on the day of protocol initiation (Day 0), after 14 days (Day 14), 21 days (Day 21), and 35 days (Day 35). | |
Secondary | To investigate pennation angle of the rectus femoris muscle. | The pennation angle will be calculated by the intersection of the path between the fascia with the lower aponeurosis of the rectus femoris muscle, measured in degrees. | The data will be collected on the day of protocol initiation (Day 0), after 14 days (Day 14), 21 days (Day 21), and 35 days (Day 35). | |
Secondary | To investigate changes in quadriceps femoral muscle strength. | It will be obtained using digital dynamometry through 3 measurements, with a one-minute interval, and the highest obtained value will be considered, measured in Newtons (N). | The data will be collected on the day of protocol initiation (Day 0), after 14 days (Day 14), 21 days (Day 21), and 35 days (Day 35). | |
Secondary | To investigate changes in arterial blood pressure during the protocol. | Assessed by blood pressure measured by intra aortic baloon pump. | Immediately before and after the end of the protocol. | |
Secondary | To investigate changes in heart rate during the protocol. | Measured by invasive blood pressure monitoring. | Immediately before and after the end of the protocol. | |
Secondary | To investigate changes in peripheral oxygen saturation during the protocol. | Measured by pulse oximetry. | Immediately before and after the end of the protocol. | |
Secondary | To investigate changes in the veno-arterial difference in carbon dioxide partial pressure. | Measured by blood gas analysis sample. | Immediately before and after the end of the protocol. | |
Secondary | To investigate adverse events: | Bleeding at the femoral insertion or changes in the functioning of the IABP, occurrence of acute arrhythmia or hemodynamic instability ( MAP < 60 mmHg or >120 mmHg or HR < 60 bpm or > 120 bpm). | In each intervention period (5 days a week for 21 days). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|